Consideration of serum glucose levels during malignant mediastinal lymph node detection in non‐small‐cell lung cancer by FDG‐PET

Glucose and FDG compete for uptake by cancers. Here, we undertook to improve diagnostic accuracy of FDG‐PET for determining mediastinal lymph node (LN) status in NSCLC by considering serum glucose level.

[1]  Y. Nishiwaki,et al.  Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. , 2005, Lung cancer.

[2]  Kyung-Ja Cho,et al.  Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[4]  D. Wood,et al.  The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. , 2002, The Journal of thoracic and cardiovascular surgery.

[5]  R. Wahl,et al.  Expression of hexokinase II and Glut-1 in untreated human breast cancer. , 2002, Nuclear medicine and biology.

[6]  D. Shelton,et al.  Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. , 2002, The Journal of surgical research.

[7]  T. Saga,et al.  Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  M. Graham,et al.  Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? , 2002, The Annals of thoracic surgery.

[9]  B. Weynand,et al.  PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[10]  P. Valk,et al.  Factors associated with false-positive staging of lung cancer by positron emission tomography. , 2000, The Annals of thoracic surgery.

[11]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[12]  S. Reske,et al.  How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer? , 2000, The thoracic and cardiovascular surgeon.

[13]  W. Chapman,et al.  Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  W C Eckelman,et al.  Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. , 1999, Cancer research.

[15]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[16]  D. Lee,et al.  Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Y. Koide,et al.  Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  G. Glatting,et al.  FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Hustinx,et al.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. , 1997, The European respiratory journal.

[21]  C. Mountain,et al.  Regional lymph node classification for lung cancer staging. , 1997, Chest.

[22]  R. Wahl,et al.  Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. , 1997, Radiology.

[23]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[24]  J. Keyes.  SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  E. Rota Kops,et al.  The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  R L Wahl,et al.  Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. , 1992, Radiology.

[27]  V. Chen,et al.  Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. , 2005, The Annals of thoracic surgery.

[28]  T. Smith,et al.  The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. , 2001, Nuclear medicine and biology.

[29]  U Ruotsalainen,et al.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.